These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 25375367

  • 1. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L, Mao L, Rodriguez SC, Hulihan J, Starr HL.
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [Abstract] [Full Text] [Related]

  • 2. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
    Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL.
    J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
    McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS.
    JAMA; 2014 May 21; 311(19):1978-87. PubMed ID: 24846035
    [Abstract] [Full Text] [Related]

  • 5. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia.
    Alphs L, Mao L, Lynn Starr H, Benson C.
    Schizophr Res; 2016 Feb 21; 170(2-3):259-64. PubMed ID: 26742509
    [Abstract] [Full Text] [Related]

  • 6. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 7. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.
    Clin Schizophr Relat Psychoses; 2014 Jul 01; 8(2):101-9, 109A. PubMed ID: 23446197
    [Abstract] [Full Text] [Related]

  • 8. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.
    J Psychopharmacol; 2011 May 01; 25(5):685-97. PubMed ID: 20615933
    [Abstract] [Full Text] [Related]

  • 9. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA, Sliwa JK, Ma YW, Fu DJ, Alphs L.
    BMC Psychiatry; 2011 May 10; 11():79. PubMed ID: 21569242
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L, Kamat SA, Sapin C, Baker RA, Eramo A, Ortendahl J, Gutierrez B, Hansen K, Bentley TG.
    J Med Econ; 2014 Aug 10; 17(8):567-76. PubMed ID: 24758296
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E, Kozma CM, Benson CJ, Mao L, Starr HL, Alphs L, Fastenau J.
    J Med Econ; 2015 Aug 10; 18(8):637-45. PubMed ID: 25851616
    [Abstract] [Full Text] [Related]

  • 12. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L.
    Curr Med Res Opin; 2010 Feb 10; 26(2):377-87. PubMed ID: 20001492
    [Abstract] [Full Text] [Related]

  • 13. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
    Alphs L, Bossie C, Mao L, Lee E, Starr HL.
    Early Interv Psychiatry; 2018 Feb 10; 12(1):55-65. PubMed ID: 26403322
    [Abstract] [Full Text] [Related]

  • 14. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.
    BMC Psychiatry; 2012 Mar 28; 12():26. PubMed ID: 22455454
    [Abstract] [Full Text] [Related]

  • 15. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
    Owen RT.
    Drugs Today (Barc); 2010 Jul 28; 46(7):463-71. PubMed ID: 20683501
    [Abstract] [Full Text] [Related]

  • 16. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.
    Schizophr Res; 2010 Feb 28; 116(2-3):107-17. PubMed ID: 19959339
    [Abstract] [Full Text] [Related]

  • 17. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.
    Int Clin Psychopharmacol; 2014 Jan 28; 29(1):45-55. PubMed ID: 24113628
    [Abstract] [Full Text] [Related]

  • 18. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L.
    J Clin Psychiatry; 2015 Mar 28; 76(3):253-62. PubMed ID: 25562685
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J, Mahlich J, Greiner W, Heres S.
    Appl Health Econ Health Policy; 2013 Oct 28; 11(5):509-21. PubMed ID: 23975630
    [Abstract] [Full Text] [Related]

  • 20. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
    Perry R, Wolberg J, DiCrescento S.
    Am J Health Syst Pharm; 2012 Jan 01; 69(1):40-3. PubMed ID: 22180550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.